RhumbLine Advisers’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

RhumbLine Advisers’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-760	Closed	-$16K	–	3269
2022 Q1	$16K	Sell	760 -79	-9%	-$2.73K	﹤0.01%	3004
2021 Q4	$50K	Hold	839	–	–	﹤0.01%	2981
2021 Q3	$79K	Sell	839 -26	-3%	-$3.46K	﹤0.01%	3007
2021 Q2	$143K	Buy	+865	New	+$147K	﹤0.01%	2948

Other funds holding TLIS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RhumbLine Advisers's TLIS Position: Q2 2022 in Review

RhumbLine Advisers sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q2 2022, closing a stake of 760 shares — an estimated $16K sold.

RhumbLine Advisers first reported a position in TLIS in Q2 2021 and held it in 4 quarters. The position peaked at $143K in Q2 2021. 35 funds tracked by Wall St. Rank hold TLIS as of Q2 2022.

RhumbLine Advisers reported no remaining Talis Biomedical Corporation Common Stock position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 760 Talis Biomedical Corporation Common Stock shares in Q2 2022, an estimated $16K.
RhumbLine Advisers first reported a position in Talis Biomedical Corporation Common Stock in Q2 2021 and held it in 4 quarters.
RhumbLine Advisers's Talis Biomedical Corporation Common Stock position peaked at $143K in Q2 2021.
35 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.